The findings were site-reported and limited to 30 days of follow-up, but this reflects a successful rollout, Wayne Batchelor says.

How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.

June is not as busy as May when it comes to medical meetings, although multiple stories from the recent New York Valves 2026 conference feature in the most-read articles from the past month. TAVI news ...

The update seeks to move on from strict LVEF cutoffs and provide a clearer and more consistent framework for clinicians.

An opt-out system seems to help, but there’s more work to do to meet performance goals endorsed by the AHA and ACC.

A novel nickel-free, low-profile TAVI valve shows promise in treating severe aortic stenosis, according to first-in-human ...

A small orifice area on its own should not dissuade operators from offering the procedure as an option, a researcher says.

Medically tailored meals, nurses front and center for prevention, GLP-1s and muscle mass in cardiac rehab, and more.

Patients who undergo mitral transcatheter edge-to-edge repair (M-TEER) for symptomatic severe mitral regurgitation (MR) have ...

Attendees will find 30 late-breaking clinical science and innovation presentations, the LAAC Summit, puppies, and more.

A systematic program designed to close the diagnosis and treatment gaps for patients with aortic stenosis (AS) seems to be on ...

Juan Granada and Nicolas Van Mieghem share an overview of the data presented on day 2 of NY Valves.